Literature DB >> 25576367

Comorbid substance use disorders in schizophrenia: a latent class approach.

Berit Kerner1.   

Abstract

Schizophrenia is a complex psychiatric disorder with a characteristic disease course and heterogeneous etiology. While substance use disorders and a family history of psychosis have individually been identified as risk factors for schizophrenia, it is less well understood if and how these factors are related. To address this deficiency, we examined the relationship between substance use disorders and family history of psychosis in a sample of 1219 unrelated patients with schizophrenia. The lifetime rate of substance use disorders in this sample was 50%, and 30% had a family history of psychosis. Latent class mixture modeling identified three distinct patient subgroups: (1) individuals with low probability of substance use disorders; (2) patients with drug and alcohol abuse, but no symptoms of dependence; and (3) patients with substance dependence. Substance use was related to being male, to a more severe disease course, and more acute symptoms at assessment, but not to an earlier age of onset of schizophrenia or a specific pattern of positive and negative symptoms. Furthermore, substance use in schizophrenia was not related to a family history of psychosis. The results suggest that substance use in schizophrenia is an independent risk factor for disease severity and onset.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Dependence; Disease course; Family history of psychosis; Major depressive disorder; Schizophrenia; Substance use disorders

Mesh:

Year:  2014        PMID: 25576367      PMCID: PMC4378564          DOI: 10.1016/j.psychres.2014.12.006

Source DB:  PubMed          Journal:  Psychiatry Res        ISSN: 0165-1781            Impact factor:   3.222


  65 in total

1.  New models of collaboration in genome-wide association studies: the Genetic Association Information Network.

Authors:  Teri A Manolio; Laura Lyman Rodriguez; Lisa Brooks; Gonçalo Abecasis; Dennis Ballinger; Mark Daly; Peter Donnelly; Stephen V Faraone; Kelly Frazer; Stacey Gabriel; Pablo Gejman; Alan Guttmacher; Emily L Harris; Thomas Insel; John R Kelsoe; Eric Lander; Norma McCowin; Matthew D Mailman; Elizabeth Nabel; James Ostell; Elizabeth Pugh; Stephen Sherry; Patrick F Sullivan; John F Thompson; James Warram; David Wholley; Patrice M Milos; Francis S Collins
Journal:  Nat Genet       Date:  2007-09       Impact factor: 38.330

2.  Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization.

Authors:  Daniel J Foti; Roman Kotov; Lin T Guey; Evelyn J Bromet
Journal:  Am J Psychiatry       Date:  2010-05-17       Impact factor: 18.112

Review 3.  Maternal infection and schizophrenia: implications for prevention.

Authors:  Alan S Brown; Paul H Patterson
Journal:  Schizophr Bull       Date:  2010-12-06       Impact factor: 9.306

4.  Genomewide linkage scan of 409 European-ancestry and African American families with schizophrenia: suggestive evidence of linkage at 8p23.3-p21.2 and 11p13.1-q14.1 in the combined sample.

Authors:  Brian K Suarez; Jubao Duan; Alan R Sanders; Anthony L Hinrichs; Carol H Jin; Cuiping Hou; Nancy G Buccola; Nancy Hale; Ann N Weilbaecher; Deborah A Nertney; Ann Olincy; Susan Green; Arthur W Schaffer; Christopher J Smith; Dominique E Hannah; John P Rice; Nancy J Cox; Maria Martinez; Bryan J Mowry; Farooq Amin; Jeremy M Silverman; Donald W Black; William F Byerley; Raymond R Crowe; Robert Freedman; C Robert Cloninger; Douglas F Levinson; Pablo V Gejman
Journal:  Am J Hum Genet       Date:  2006-01-03       Impact factor: 11.025

5.  The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study.

Authors:  Louisa Degenhardt; Chris Tennant; Stuart Gilmour; David Schofield; Louise Nash; Wayne Hall; Diana McKay
Journal:  Psychol Med       Date:  2007-02-09       Impact factor: 7.723

Review 6.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.

Authors:  Theresa H M Moore; Stanley Zammit; Anne Lingford-Hughes; Thomas R E Barnes; Peter B Jones; Margaret Burke; Glyn Lewis
Journal:  Lancet       Date:  2007-07-28       Impact factor: 79.321

7.  Correlates of patterns of substance abuse among patients with schizophrenia.

Authors:  B J Cuffel; K A Heithoff; W Lawson
Journal:  Hosp Community Psychiatry       Date:  1993-03

8.  Exome sequencing supports a de novo mutational paradigm for schizophrenia.

Authors:  Bin Xu; J Louw Roos; Phillip Dexheimer; Braden Boone; Brooks Plummer; Shawn Levy; Joseph A Gogos; Maria Karayiorgou
Journal:  Nat Genet       Date:  2011-08-07       Impact factor: 38.330

9.  Genome-wide association study in bipolar patients stratified by co-morbidity.

Authors:  Berit Kerner; Christophe G Lambert; Bengt O Muthén
Journal:  PLoS One       Date:  2011-12-21       Impact factor: 3.240

10.  Prognosis of schizophrenia in persons with and without a history of cannabis use.

Authors:  E Manrique-Garcia; S Zammit; C Dalman; T Hemmingsson; S Andreasson; P Allebeck
Journal:  Psychol Med       Date:  2014-09       Impact factor: 7.723

View more
  2 in total

1.  Suppression of Methamphetamine Self-Administration by Ketamine Pre-treatment Is Absent in the Methylazoxymethanol (MAM) Rat Model of Schizophrenia.

Authors:  Jana Ruda-Kucerova; Zuzana Babinska; Tibor Stark; Vincenzo Micale
Journal:  Neurotox Res       Date:  2017-04-18       Impact factor: 3.911

2.  Patterns of Management of Patients With Dual Disorder (Psychosis) in Italy: A Survey of Psychiatrists and Other Physicians Focusing on Clinical Practice.

Authors:  Massimo Clerici; Andrea de Bartolomeis; Sergio De Filippis; Giuseppe Ducci; Icro Maremmani; Giovanni Martinotti; Fabrizio Schifano
Journal:  Front Psychiatry       Date:  2018-11-13       Impact factor: 4.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.